Research Article
Incidence and Prognostic Impact of DNMT3A Mutations in Korean Normal Karyotype Acute Myeloid Leukemia Patients
Table 3
Comparison of demographic and clinical features in all 67 NK AML patients with respect to DNMT3A nonsynonymous variation status.
| | Clinical characteristics | DNMT3A nonsynonymous variation status | value | DNMT3A deleterious mutation status | value | DNMT3A R882 mutation status | value | | No variation () | Variation () | No mutation () | Mutation () | No mutation () | Mutation () |
| | Sex (M : F)* | 33 : 24 | 4 : 6 | NS | 34 : 26 | 3 : 4 | NS | 35 : 27 | 2 : 3 | NS | | Age, years, median (range)** | 56.0 (11.0–80.0) | 62.0 (18.0–83.0) | NS | 56.0 (11.0–80.0) | 59.0 (18.0–83.0) | NS | 56.0 (11.0–83.0) | 59.0 (18.0–77.0) | NS | | Laboratory findings at diagnosis, median (range) | | | | | | | | | | | WBC (109/L)** | 35.6 (0.9–368.9) | 63.8 (0.6–282.2) | NS | 36.3 (0.6–368.9) | 55.5 (0.9–206.0) | NS | 33.6 (0.6–368.9) | 72.2 (0.9–206.0) | NS | | Hb (g/dL)** | 8.6 (5.4–14.2) | 7.7 (5.6–10.7) | NS | 8.6 (5.4–14.2) | 7.3 (5.6–10.7) | NS | 8.6 (5.4–14.2) | 7.3 (5.6–10.7) | 0.097 | | Platelets (109/L)** | 54.0 (5.0–172.0) | 62.0 (38.0–270.0) | NS | 54.0 (5.0–172.0) | 96.0 (43.0–270.0) | NS | 53.5 (5.0–172.0) | 113.0 (51.0–270.0) | NS | | BM blasts (%)** | 73.0 (22.1–97.0) | 74.3 (29.5–96.2) | NS | 72.9 (22.1–97.0) | 75.0 (29.5–84.3) | NS | 72.9 (22.1–97.0) | 75.0 (29.5–84.3) | NS | | FLT3 ITD mutation (%)* | 11/45 (24.4) | 4/6 (66.7) | 0.054 | 12/47 (25.5) | (75.0) | 0.071 | 12/47 (25.5) | (75.0) | 0.071 | | FLT3 D835 mutation (%)* | 2/45 (4.4) | 0/6 (0.0) | NS | 2/47 (4.3) | 0/4 (0.0) | NS | 2/47 (4.3) | 0/4 (0.0) | NS | | CR rates (%)* | 33/57 (57.9) | 3/10 (30.0) | NS | 34/60 (56.7) | 2/7 (28.6) | NS | 34/62 (54.8) | 2/5 (40.0) | NS | | Interval from Dx to CR, days, median (range)** | 34.0 (21.0–83.0) | 53.0 (25.0–164.0) | NS | 35.0 (21.0–164.0) | 39.0 (25.0–53.0) | NS | 35.0 (21.0–164.0) | 39.0 (25.0–53.0) | NS | | Relapse rates (%)* | 16/33 (48.5) | 1/3 (33.3) | NS | 17/34 (50.0) | 0/2 (0.0) | NS | 17/34 (50.0) | 0/2 (0.0) | NS | | Death rates (%)* | 31/57 (54.4) | 5/10 (50.0) | NS | 34/60 (56.7) | 2/7 (28.6) | NS | 34/62 (54.8) | 2/5 (40.0) | NS | | SCT performance rates (%)* | 19/57 (33.3) | 1/10 (10.0) | NS | 19/60 (31.7) | 1/7 (14.3) | NS | 19/62 (30.6) | 1/5 (20.0) | NS |
|
|
Note: values were obtained from Chi-square test/Fisher’s exact test* and Mann-Whitney test**.
WBC: white blood cell; Hb: hemoglobin; BM: bone marrow; FLT3: fms-related tyrosine kinase 3; ITD: internal tandem duplications; D: aspartate; CR: complete remission; Dx: diagnosis; SCT: stem cell transplantation; DNMT3A: DNA methyltransferase 3A; R: arginine; NS: not significant.
|
